Vitamin D Pilot Study in Patients With Multiple Sclerosis

Phase 1 study of 19-nor Vitamin D in relapsing-remitting MS. Primary measure is MRI.

Completed

Looking for future studies?

Key information

Conditions

Relapsing Remitting Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting Nervous System Diseases

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

UW-Madison

Madison, Wisconsin, 53792, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

relapsing remitting MS

Exclusion criteria

MRI contraindicated

Treatment and study plan

19 nor vitamin d

Drug

Primary outcomes

MRI Measure of new active lesions, observation vs. treatment

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Registry information

Important dates

Study start: 1998
Primary completion: 2000
Study completion: 2000
First posted: Dec 10, 2010
Registry last updated: Oct 5, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed